Finance

Lists
PIG:FRA
Perrigo Company PLC
€12.64
+4.16%
(+0.51) 1D
Sep 7, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for PIG...
Open
€12.64
High
€12.64
Low
€12.64
Mkt. cap
2.07B
Avg. vol.
51.00
Volume
0.00
52-wk high
€19.85
52-wk low
€7.82
No. of employees
8K
Open
€12.64
High
€12.64
Low
€12.64
Mkt. cap
2.07B
Avg. vol.
51.00
Volume
0.00
52-wk high
€19.85
52-wk low
€7.82
No. of employees
8K
Profile
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value. Wikipedia
About Perrigo Company PLC
CEOMurray S. Kessler
Employees8.1K
Founded1887
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.04B
1.11B
969.20M
1.02B
Cost of goods sold
666.20M
747.40M
643.70M
708.90M
Cost of revenue
666.20M
747.40M
643.70M
708.90M
Research and development expenses
24.90M
21.80M
24.60M
23.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
245.70M
255.60M
267.30M
251.20M
Operating expense
283.50M
249.00M
291.90M
274.60M
Total operating expenses
949.70M
996.40M
935.60M
983.50M
Operating income
93.60M
113.20M
33.60M
39.30M
Other non operating income
300.00K
-10.70M
3.70M
10.10M
EBT including unusual items
22.40M
-1.33B
-408.60M
105.50M
EBT excluding unusual items
43.20M
68.70M
-1.30M
-8.50M
Income tax expense
9.70M
82.90M
-18.70M
16.90M
Effective tax rate
43.30%
-6.23%
4.58%
16.02%
Other operating expenses
12.90M
-28.40M
-
-300.00K
Net income
7.50M
-1.42B
-398.60M
74.50M
Net profit margin
0.72%
-127.80%
-41.13%
7.28%
Earnings per share
0.80
0.77
0.43
0.50
Interest and investment income
-
-
-
-
Interest expense
-50.10M
-52.80M
-49.00M
-47.00M
Net interest expenses
-50.10M
-52.80M
-49.00M
-47.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
179.00M
199.10M
116.90M
116.20M
Gain or loss from assets sale
-
-
-
-129.50M
AI content may include mistakes. Learn more
Google apps